<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                 UNITED STATES

                                SECURITIES AND EXCHANGE COMMISSION
                                            WASHINGTON ,    D .C . 20549



     D IVI S IO N OF
CO RP ORAT IO N FINANCE




                                                                  June 11, 2018

Amro Albanna
Chief Executive Officer
ADiTx Therapeutics, Inc.
11161 Anderson St., Suite 105-10014
Loma Linda, CA 92354

           Re: ADiTx Therapeutics, Inc.
               Amendment No. 1 to Offering Statement on Form 1-A
               Filed on May 25, 2018
               File No. 024-10825

Dear Mr. Albanna:

      We have reviewed your amended offering statement and have the following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your offering statement and
providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your offering statement and the
information you
provide in response to these comments, we may have additional comments. Unless
we note
otherwise, our references to prior comments are to comments in our April 26,
2018 letter.

Amendment No. 1 to Offering Statement on Form 1-A

General

1.        We note that Article 9 of your Amended and Restated Certificate of
Incorporation
          includes an exclusive forum provision. Please include disclosure in
your offering
          statement, under "Securities Being Offered," at page 46, about the
provision, its scope, its
          enforceability and its potential impact on the rights of investors.
Please also include a risk
          factor to discuss the effects of the provision, including the
possibility that the exclusive
          forum provision may discourage stockholder lawsuits, or limit
stockholders' ability to
          bring a claim in a judicial forum that it finds favorable for
disputes with the company and
 Amro Albanna
FirstName LastNameAmro Albanna
ADiTx Therapeutics, Inc.
Comapany NameADiTx Therapeutics, Inc.
June 11, 2018
June 11, 2018 Page 2
Page 2
FirstName LastName
         its officers and directors.
2.       We note your disclosure throughout the offering statement that the
minimum offering
         amount is "$6,000,000 of Units, or such greater amount of Units
required for approval of
         [your] securities to commence trading on the NASDAQ Capital Market."
Please revise
         throughout to remove references to the greater amount that may be
required to receive
         Nasdaq approval and set a specific numeric amount for the minimum
offering, or advise.
         Also, please advise how you plan to comply with Rules 10b-9 and 15c2-4
if you do not
         include a specific minimum offering amount.
3.       Please refer to Exhibit 12.1. Please remove the first sentence in the
last paragraph on page
         1 of the opinion, as it appears to be an assumption regarding whether
the shares are legally
         issued, or advise.
Cover Page

4.       We note your disclosure that "[t]he minimum investment is $600 (100
Units), however the
         Company reserves the right to accept investments for less than $600"
and your reference
         to the Securities Being Offered section on page 46. We also note that
there is no
         additional information about this minimum investment on page 46 or in
any other section
         of the offering statement. Please revise to explain what criteria, if
any, you will use to
         determine whether to accept investments in the amount of less than
$600.
Exhibits

5.       Please file the executed copy of the Escrow Deposit Agreement,Exhibit
6.4, prior to
         qualification.
6.       Please have counsel revise Exhibit 12.1 to also address the legality
of the warrants and
         units. Refer to Section II.B.1.h of Staff Legal Bulletin No. 19,
available on our
         website www.sec.gov.
7.       We note the test the waters materials filed as exhibit 13.1. We also
note that those
         materials indicate that a comprehensive list of the patent portfolio
is available upon
         request. Please advise if, or how, that list differs from exhibit A,
Patent Rights, in Exhibit
         6.1, Patent and Technology License Agreement. If that is not the same
information as you
         are requesting confidential treatment for, please provide us with the
materials that you
         indicate are available upon request, as referenced in the test the
waters materials. Also,
         please advise if the materials available upon request have been
requested, and already
         given to potential investors.
 Amro Albanna
ADiTx Therapeutics, Inc.
June 11, 2018
Page 3

       You may contact Abe Friedman at (202) 551-8298 or Jean Yu at (202)
551-3305 if
you have questions regarding comments on the financial statements and related
matters.
Please contact Tonya K. Aldave at (202) 551-3601 or Susan Block at (202)
551-3210 with any
otherquestions.


FirstName LastNameAmro Albanna
                                                         Division of
Corporation Finance
Comapany NameADiTx Therapeutics, Inc.
                                                         Office of
Transportation and Leisure
June 11, 2018 Page 3
cc:       Richard Friedman
FirstName LastName
</TEXT>
</DOCUMENT>
